Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Böhler
T
T
Herr
I
I
Debatin
K M
KM
Geiss
M
M
Haas
J
J
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002648:Child; D016049:Didanosine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D053222:Fas Ligand Protein; D005786:Gene Expression Regulation / Q000187:drug effects; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects*; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use; D019014:fas Receptor / Q000276:immunology*
D019380:Anti-HIV Agents; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D018894:Reverse Transcriptase Inhibitors; D019014:fas Receptor; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine